The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy

被引：3
|
作者：
Li, Qi [1 ]
Li, Li [1 ]
Wang, Yuchao [1 ]
Xu, Chunhua [1 ,4 ]
Zou, Jue [2 ,3 ]
机构：
[1] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
[4] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
来源：
HELIYON | 2023年 / 9卷 / 09期
关键词：
SCLC; Chemotherapy; Prognosis; AFR; INFLAMMATION;
D O I：
10.1016/j.heliyon.2023.e19225
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
This study examined the role of pretreatment albumin-to-fibrinogen ratio (AFR) in the prognosis of small-cell lung cancer (SCLC) patients receiving first-line platinum-based chemotherapy. A total of 131 SCLC patients were enrolled. The predictive value of the AFR for progression free survival (PFS) and overall survival (OS) were evaluated by receiver operating characteristic (ROC) curve analysis. The predictive factor of survival was assessed by univariate and multivariate Cox proportional regression analysis. The correlation between OS, PFS and AFR was determined by the log-rank test using the Kaplan-Meier method. AFR was an effective predictor of OS in SCLC patients with a cut-off value of 7.78. AFR was independent risk factors for OS and PFS. Kaplan Meier analysis showed that PFS and OS in patients with high AFR levels were significantly higher than those with low AFR levels. These results suggest that AFR could be an effective predictor of survival in patients with SCLC.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] High glasgow prognostic score associates with a poor survival in Chinese advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
    Su, Keju
    Wang, Xu
    Chi, Lumei
    Liu, Yang
    Jin, Lina
    Li, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 16353 - 16359
  • [32] A New Prognostic Index in Chinese Patients With Metastatic Non-Small Cell Lung Cancer Receiving First-Line Chemotherapy
    Yu, Hui
    Wang, Jialei
    Liu, Fang
    Sansas, Benoit
    Preville, Xavier
    Wu, Xianghua
    Meng, Xia
    Chang, Jianhua
    Micol, Romain
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S723 - S724
  • [33] Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer
    Fang, Shu
    Wang, Zhehai
    Guo, Jun
    Liu, Jie
    Li, Changzheng
    Liu, Lin
    Shi, Huan
    Liu, Liyan
    Li, Huihui
    Xie, Chao
    Zhang, Xia
    Sun, Wenwen
    Li, Minmin
    ONCOTARGETS AND THERAPY, 2014, 7 : 1185 - 1193
  • [34] Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy
    Zhu, Kaibo
    Jiang, Minlin
    Xu, Yi
    Chen, Peixin
    Wang, Hao
    Yu, Jia
    Zhu, Jun
    Zhao, Wencheng
    Meng, Die
    He, Yayi
    JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 1205 - 1214
  • [35] The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy
    Lee, Siow Ming
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Rudd, Robin
    Ngai, Yenting
    Edwards, Alex
    Hackshaw, Allan
    EUROPEAN JOURNAL OF CANCER, 2019, 120 : 86 - 96
  • [36] Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    Lisberg, Aaron
    Garon, Edward Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) : 529 - +
  • [37] New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small cell lung cancer
    Manegold, Christian
    CLINICAL LUNG CANCER, 2008, 9 : S100 - S108
  • [38] Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy
    Leprieur, E. Giroux
    Antoine, M.
    Vieira, T.
    Duruisseaux, M.
    Poulot, V.
    Rabbe, N.
    Belmont, L.
    Gounant, V.
    Lavole, A.
    Milleron, B.
    Lacave, R.
    Cadranel, J.
    Wislez, M.
    LUNG CANCER, 2013, 79 (02) : 167 - 172
  • [39] Prognostic value of C-reactive protein/albumin ratio in patients receiving first-line palliative chemotherapy with unresectable stage IV gastric cancer
    Ni, Xue-Feng
    Wu, Jun
    Ji, Mei
    Shao, Ying-Jie
    Zhou, Wen-Jie
    Jiang, Jing-Ting
    Wu, Chang-Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (12): : 12785 - 12796
  • [40] KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
    Ghimessy, Aron Kristof
    Gellert, Aron
    Schlegl, Erzsebet
    Hegedus, Balazs
    Raso, Erzsebet
    Barbai, Tamas
    Timar, Jozsef
    Ostoros, Gyula
    Megyesfalvi, Zsolt
    Gieszer, Balazs
    Moldvay, Judit
    Renyi-Vamos, Ferenc
    Lohinai, Zoltan
    Hoda, Mir Alireza
    Klikovits, Thomas
    Klepetko, Walter
    Laszlo, Viktoria
    Dome, Balazs
    CANCERS, 2019, 11 (10)
12345